Leukemias, lymphomas, and other hematologic cancers

Drug Name

• “Another CAR in the Garage”: Q&A on CAR-T With UPenn’s Bruce Levine, PhD
• “Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
• A Case of Intra-Abdominal Follicular Lymphoma Presenting as Heart Failure
• ADCETRIS
• Age at Diagnosis of Myeloproliferative Neoplasm Affects Pattern of Thrombotic Events but Not Mortality Risk
• ALIQOPA
• ALKERAN
• ALKERAN FOR INJECTION
• An Integrated Analysis for Selecting Ibrutinib-Based Combination Therapy in CLL
• ARRANON
• ARZERRA
• BCMA CAR-T bb2121 Appears to Be Safe and Effective in Multiple Myeloma
• BELEODAQ
• BENDEKA
• BESPONSA
• BEXXAR
• BICNU
• Biological Differences Between 2 Rare Leukemias Do Not Influence Clinical Outcomes
• Bleomycin
• BLINCYTO
• BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
• BOSULIF
• BUSULFEX
• CALQUENCE
• CAMPATH
• CAR-T in Multiple Myeloma: Promising Efficacy and Generally Manageable Toxicity
• Carfilzomib Dosing and Scheduling in Newly Diagnosed Multiple Myeloma
• CD33 and MPC-1: Monitoring Response to Bortezomib in Multiple Myeloma
• Cerebrovascular Disease: A Serious Complication After Allogeneic Hematopoietic Stem Cell Transplantation
• CERUBIDINE
• Changes in Hematologic Parameters Following Pesticide Exposure
• Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
• Cladribine
• Clinical Outcomes in Philadelphia-Negative ALL With Inotuzumab Ozogamicin Plus Chemotherapy
• CLOLAR
• clonoSEQ and MRD Testing in Multiple Myeloma and ALL
• Combination Regimen for Pretransplant Conditioning May Improve Outcomes for Patients With Multiple Myeloma
• Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
• Comparing Efficacy and Safety of Auto-HCT in Older and Younger Patients With Multiple Myeloma
• Consensus Panel on Maintenance Therapies Following Autologous Hematopoietic Cell Transplantation in Lymphoma
• Contrast-Enhanced MRI Characterization of Brain Cancers
• COPIKTRA
• Cure Rate Disparities Among Children With Burkitt Lymphoma
• Cyclophosphamide
• Cyclophosphamide Injection
• Cytarabine
• Cytogenetic Abnormalities Provide Prognostic Value in Predicting Acute Myeloid Leukemia Outcomes
• Dacarbazine
• DACOGEN
• DARZALEX
• Data Mining to Develop Mutation-Specific Treatments in Acute Myeloid Leukemia
• DAURISMO
• Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
• DEPOCYT
• Designing a Clinical Trial to Evaluate Multistage Treatment Approaches in CLL
• Direct-Acting Oral Anticoagulant Treatment for Acute Venous Thromboembolism
• Disease Progression Is Associated With Increased Costs for Patients With Hematologic Malignancies
• DOXIL
• Doxorubicin HCl
• Doxorubicin HCl Solution
• Early Treatment for Smoldering Multiple Myeloma
• EBV Reactivation After Transplant Associated With Worse Clinical Outcomes in Myelodysplastic Syndrome
• Effects of HLA Dimorphism on Clinical Outcomes of Immunotherapy in Acute Myeloid Leukemia
• ELZONRIS
• EMPLICITI
• ERWINAZE
• EVOMELA
• Extranodal and Spleen Involvement Predict Outcomes in Follicular Lymphoma
• FARYDAK
• FDA Panel Backs Pexidartinib for Rare Tumor, Votes Against Quizartinib for FLT3-ITD AML
• Fludarabine
• Follicular Lymphoma With Extranodal Disease Only: When to Suspect Systemic Disease
• FOLOTYN
• GAZYVA
• GLEEVEC
• GLEOSTINE
• High 5-Year OS Rate for Children and Young Adults with Relapsed/Refractory Hodgkin Lymphoma Receiving Moderate-Dose Salvage RT
• HYDREA
• ICLUSIG
• IDAMYCIN PFS
• Idarubicin
• IDHIFA
• Imaging Studies Critical in Distinguishing Extramedullary Disease in Multiple Myeloma Diagnosis
• IMBRUVICA
• IMBRUVICA TABLETS
• Improved Long-Term Outcomes After Stronger Postinduction Intensification for Acute Lymphoblastic Leukemia
• Intensive Chemotherapy May Be Beneficial for Younger Patients With Myelodysplastic Syndrome
• Intravenous Busulfan Plus Melphalan vs Melphalan Alone as a Conditioning Regimen in Multiple Myeloma: Is There a Difference?
• INTRON A
• INTRON A SOLN
• ISTODAX
• JAKAFI
• KEYTRUDA
• KYMRIAH
• KYPROLIS
• Lack of Thromboprophylactic Benefit With Rivaroxaban in Ambulatory Patients With Cancer
• LEUKERAN
• LUMOXITI
• Managing Neutropenic Sepsis in Patients With Cancer
• Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes
• MARQIBO
• MATULANE
• MEK Inhibition Spurs Durable Responses in Patients With Histiocytic Neoplasms
• Mercaptopurine
• Methotrexate for injection
• Methotrexate injection
• Mitoxantrone HCl
• Molecular Characterization of Pediatric Follicular Lymphoma
• Muscle Complaints Are a Frequent Side Effect of TKI Use in CML, but What Causes Them?
• MUSTARGEN
• Myeloma Trial Aims to Use Genetic Profile for Treatment Optimization
• MYLERAN
• Nanatinostat Gets Orphan Drug Designation for EBV-Associated Cancers
• NINLARO
• No Correlation Between SF3B1 Mutation in Myelodysplastic Syndrome and Overall Survival
• ONCASPAR
• ONTAK
• OPDIVO
• Optimal Approaches to Treating Venous Thromboembolism in Patients With Cancer
• Overall Survival in Follicular Lymphoma With Complete Response Similar to General Population
• Pamidronate disodium Injection
• Patient Pain, QoL Associated With Salvage ASCT in Myeloma Must Be Balanced With Survival Benefit
• Pentostatin
• POMALYST
• Poor Outcome for Patients With Multiple Myeloma Who Are Refractory to CD38-Targeting Agent
• Postchemo Radiation Tx May Benefit Some With Hodgkin Lymphoma
• POTELIGEO
• Predicting Survival of Certain Subgroups of Patients With AML Following Allogeneic SCT
• Predictors of TKI Response in CML Remain Elusive
• Presence of Autoimmune Diseases May Increase Risk for Diffuse Large B Cell, Marginal Zone Lymphomas
• PURIXAN
• Relapse Risk in Pediatric Acute Myeloid Leukemia With Granulocyte Colony-Stimulating Factor
• Remodeled CD19 CAR Shows Clinical Benefit, Low Toxicity in B-Cell Lymphoma
• Restoring T-Cell Immunity Following Allogeneic Hematopoietic Stem Cell Transplantation
• REVLIMID
• RITUXAN
• RITUXAN HYCELA
• RYDAPT
• Second Patient Achieves Sustained HIV-1 Remission After Treatment Cessation
• Similar Health Care Costs in Older Patients With AML Regardless of Induction Intensity
• Single-Agent Acalabrutinib Meets Primary End Point of Phase 3 Study in R/R CLL
• SOX11 Status Not an Independent Prognostic Factor in Mantle Cell Lymphoma
• SPRYCEL
• Standardization of Minimal Residual Disease Measurements in Philadelphia-Positive ALL
• Study Calculates Incidence of Opportunistic Infections During Ibrutinib Therapy
• Support for Multimodality Therapy in Some Patients With Follicular Lymphoma
• Susceptibility to Radiation-Induced Breast Cancer Following Treatment for Hodgkin Lymphoma
• Sustained Efficacy and Safety of Ibrutinib in Relapsed/Refractory CLL
• SYNRIBO
• Targeted Therapy Promising for Rare Hematologic Cancer